Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

Shanghai Stock Exchange 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Gross Profit for the year ending December 31, 2023: USD 267.99 M

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Gross Profit is USD 267.99 M for the year ending December 31, 2023, a -4.90% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Gross Profit for the year ending December 31, 2022 was USD 281.81 M, a -14.35% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Gross Profit for the year ending December 31, 2021 was USD 329.01 M, a 24.96% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Gross Profit for the year ending December 31, 2020 was USD 263.29 M, a 44.90% change year over year.
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Gross Profit for the year ending December 31, 2019 was USD 181.70 M, a 48.58% change year over year.

Key data

Date	Gross Profit	Operating Income	EBIT	EBITDA

Shanghai Stock Exchange: 603707.SS

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd

CEO	Ms. Wu Guiping
IPO Date	July 19, 2017
Location	China
Headquarters	1/16 Nanjing Jiangbei New
Employees	1,451
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.

Key trends

Past 5 years